Categories
Archives
Receive Email Updates
-
-
-
Certified Licensing Professionals, Inc., 2021 
Disclaimer
This blog, Patents4Life, does not contain legal advice and is for informational purposes only. Its publication does not create an attorney-client relationship nor is it a solicitation for business. This is the personal blog of Warren Woessner and does not reflect the views of Schwegman Lundberg & Woessner, or any of its attorneys or staff. To the best of his ability, the Author provides current and accurate information at the time of each post, however, readers should check for current information and accuracy.
-
- About Me
Warren D. Woessner
Pages
Archives
Author Archives: Warren Woessner
USPTO Announces Fast-Track Ex Parte Appeals Pilot Program
July 1, 2020 USPTO Press Release: “WASHINGTON — The United States Patent and Trademark Office (USPTO) today announced plans for the Patent Trial and Appeal Board (PTAB) to begin accepting petitions for expedited resolution of ex parte appeals. The ‘Fast-Track … Continue reading
Biogen v. Mylan: When Does a Specification Fail to Describe a Newly-Presented Claim?
The disclosure requirements that will meet the written description requirement of s. 112(1) had a fairly mundane priority policing role prior to the expansion of the importance of the requirement in the biotech cases leading up to the en banc … Continue reading
Illumina v. Ariosa – Fed. Cir. Splits a Fine s. 101 Hair
Until I read that another commentator wrote that the split panel decision in Illumina v. Ariosa Diagnostics, Appeal No. 2019-1419 (Fed. Cir., March 17, 2020) struck a hopeful note in the patent eligibility wars, I confess that I had missed … Continue reading
G S Cleantech Petitions Fed. Cir. for Rehearing En Banc
Before you read this post, please read or re-read my post of March 9, 2020, that summarized the panel decision in some detail. The case involves the district court’s finding of inequitable conduct by both CleanTech and their attorneys via … Continue reading